Assuring a Future U.S.-Based Nuclear and Radiochemistry Expertise (2012)

Chapter: Appendix G: Positron Emission Tomography Radiopharmaceuticals

Previous Chapter: Appendix F: Data Collection from National Laboratories
Suggested Citation: "Appendix G: Positron Emission Tomography Radiopharmaceuticals." National Research Council. 2012. Assuring a Future U.S.-Based Nuclear and Radiochemistry Expertise. Washington, DC: The National Academies Press. doi: 10.17226/13308.

G

Positron Emission Tomography Radiopharmaceuticals

 

TABLE G-1 Positron Emission Tomography Radiopharmaceuticals

Trade Name Radiopharmaceutical Clinical Indication

Ammonia N13

13N-Ammonia

Myocardial blood flow

Cardio-Gen

82Rb-Rubidium chloride

Myocardial blood flow

Florbetapir F18 **

18F-styryl-pyridine

Amyloid Plaques Alzheimer’s disease

Fluorbetabane F18#

18F-styryl-pyridine

Amyloid Plaques Alzheimer’s disease

Flutemetamol F18#

18F-hydroxy-benzothiazole

Amyloid Plaques Alzheimer’s disease

Fluorpiridaz F18#

18F-pyridazinone

Myocardial blood flow

Fludeoxyglucose F18 Injection

18F-Fluorodeoxyglucose

Oncology,Myocardial Viability, Seizure Foci

Sodium Fluoride F18

Sodium 18F-fluoride

Bone scans



Single Photon Emission Computed Tomography (SPECT) Radiopharmaceuticals

Chromitope Mallinkrodt Cr-51

Sodium 51Cr-chromate

Red Blood Cell Labeling

Ga-67

67Ga-Gallium citrate

Soft tissue tumor, Inflammatory processes

Indium In 111 oxyquinoline

111In-Indium oxyquinoline

Luekocyte and platlet labeling

MPI Indium DTPA In 111

111In-Indium Pentetate disodium

Cerebrospinal fluid kinetics

ProstaScint

111In-Indium Capromab Pendetide

Prostate Tumor

Octreoscan

111In-Indium Pentetreotide

Neuroendocrine tumors Gastroenteropancreatic tumors

Zevalin

111In -Ibitumonmab iuxetan

non-Hodgkin’s lymphoma

Sodium Iodide I 123

Sodium 123I-iodide

Thyroid uptake

Datscan

123I-Ioflupane

Striatal Dopaminae Transporters

Adreview

123I-Iobenguane

Pheochromacytoma, Neuroblastoma

Glofil

125I-Iothalamate

Glomerular filtration measurement

Jeanatope

125I-human Serum Albumin

Total blood and plasma volume

Megatope

131I-human Serum Albumin

Total blood and plasma volume

Bexxar

131I-Tositumomab

non-Hodgkin’s lymphoma

Sodium Iodide I 123

Sodium 123I-iodide

Thyroid uptake

Technetium Generator

99mTc-Pertechnetate

Thyroid, salivary and parathyroid

Technelite

   glands, ectopic gastric mucosa,

Ultra-Technekow FM

   dacryocystography, cystography

Neurolite

99mTc-Bicisate (ECD)

Cerebral Perfusion

Hepatolite-CIS

99mTc-Disofenin (DISIDA)

Hepatobiliary function

Ceretec

99mTc-Exametazine (HMPAO)

Cerebral Perfusion

Suggested Citation: "Appendix G: Positron Emission Tomography Radiopharmaceuticals." National Research Council. 2012. Assuring a Future U.S.-Based Nuclear and Radiochemistry Expertise. Washington, DC: The National Academies Press. doi: 10.17226/13308.
Trade Name Radiopharmaceutical Clinical Indication

Pulmolite

99mTc-Aggregated albumin

Pulmonary Perfusion

Technetium Tc 99M Albumin Aggregated Kit

Choletec

99mTc-Mebrofenin

Hepatobiliary function

Osteolite

99mTc-Medronate (MDP)

Bone imaging

Technescan MAG3

99mTc-Mertiatide

Renal function

Techneplex DTPA

99mTc-Pentetate

Renal function, Radioaresol ventilation

Phosphotec Pyrolite Pyro Technescan PYP Amersham PYP

99mTc-Pyrophosphate (PYP)

Infarct imaging, in vivo Red blood cell labeling

Cardiolite Miraluma

99mTc-Sestamibi

Myocardial blood flow, Breast tumor

DMSA

99mTc-Succimer (DMSA)

Renal function

Sulfur Colloid

99mTc-Sulfur Colloid

Liver/spleen gastric emptying, GI bleeds

AN-Sulfur Colloid

Myoview

99mTc-Tetrofosmin

Myocardial blood flow

Thallium

201Tl-Thallium chloride

Myocardial blood flow, Parathyroid, Tumor

Xenon

133Xe-xenon gas

Pulmonary ventilation

Radiotherapeutics

Zevalin

90Y-Ibitumonmab Tiuxetan

non-Hodgkin’s lymphoma

Bexaar

131I-Tositumomab

non-Hodgkin’s lymphoma

Metastron

89Sr-strontium

bone pain from skeletal metastases

Quadramet

153Sm Lexidronin

bone pain from skeletal metastases

Sodium Iodide I 131

Sodium 131I-iodide

Thyroid therapy

HICON

Phosphocol 32

32P-Chromicphosphate

Intracavity malignancies

** Conditionally approved by the FDA

# in Phase 3 clinical trials

SOURCE: NRC/IOM 2007; FDA 2011; UAMS 2011

REFERENCES

FDA (U.S. Food and Drug Administration). 2011. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. U.S. Food and Drug Administration [online]. Available: http://www.accessdata.fda.gov/scripts/cder/ob/default.cfm [accessed November 21, 2011].

NRC/IOM (National Research Council and Institute of Medicine). 2007. Appendix C. Commercially available radiopharmaceuticals. Pp. 151-154 in Advancing Nuclear Medicine through Innovation. Washington, DC: The National Academies Press.

UAMS (University of Arkansas for Medical Sciences). 2011. Radiopharmaceutical List and Package Inserts. Nuclear Pharmacology, College of Pharmacy, University of Arkansas for Medical Sciences [online]. Available: http://nuclearpharmacy.uams.edu/resources/PackageInserts.asp [accessed October 24, 2011].

Suggested Citation: "Appendix G: Positron Emission Tomography Radiopharmaceuticals." National Research Council. 2012. Assuring a Future U.S.-Based Nuclear and Radiochemistry Expertise. Washington, DC: The National Academies Press. doi: 10.17226/13308.
Page 193
Suggested Citation: "Appendix G: Positron Emission Tomography Radiopharmaceuticals." National Research Council. 2012. Assuring a Future U.S.-Based Nuclear and Radiochemistry Expertise. Washington, DC: The National Academies Press. doi: 10.17226/13308.
Page 194
Next Chapter: Appendix H: Chemistry Department Chairs
Subscribe to Email from the National Academies
Keep up with all of the activities, publications, and events by subscribing to free updates by email.